Lab21's portfolio swells with new tests from deCODE
This article was originally published in Clinica
UK diagnostics firm Lab21 and Icelandic biopharmaceutical company deCODE genetics have struck up a deal to make the latter’s DNA-based tests available in the UK and Ireland. Lab21 will now distribute deCODE’s CE-marked and FDA-approved tests for genetic predisposition of type 2 diabetes, myocardial infarction, atrial fibrillation, prostate cancer and glaucoma. This deal also allows Cambridge-based Lab21 to offer new tests as they emerge from deCODE’s pipeline, including one for the increased risk of oestrogen-positive breast cancer. Financial details of the deal were not disclosed.